Background
NanoFCM Co., Ltd., headquartered in Xiamen, Fujian province, China, specializes in developing advanced analytical instruments for nanoparticle analysis. The company's mission is to provide versatile platforms for the multiparameter analysis of functional nanoparticles at the single-particle level, thereby enhancing research in life sciences, nanoscience, and nanotechnology.
Key Strategic Focus
NanoFCM's strategic focus centers on delivering high-sensitivity and high-resolution measurement solutions for sub-micron particles. Their flagship product, the NanoAnalyzer, enables comprehensive characterization of nanoparticles, including size distribution, concentration, and biochemical properties. This technology is particularly significant in fields such as extracellular vesicle research, gene therapy, vaccine development, and drug delivery systems.
Technological Platform and Innovation
NanoFCM's NanoAnalyzer platform is built upon nano-flow cytometry technology, which allows for the analysis of nanoparticles as small as 7 nm for metallic particles and 40 nm for biological entities. Key features include:
- High Sensitivity and Resolution: Achieves sensitivity for scatter detection below 30 nm and resolution comparable to transmission electron microscopy (TEM) at 40/50 nm.
- Multiparameter Analysis: Enables simultaneous measurement of size, concentration, and biochemical properties through concurrent multi-color fluorescence detection.
- High Throughput: Processes large sample volumes efficiently, facilitating extensive clinical studies and rapid data acquisition.
Leadership Team
- Dr. Shaobin Zhu: CEO of NanoFCM Inc., overseeing the company's strategic direction and global operations.
- Dr. Dimitri Aubert: Managing Director of NanoFCM Co., Ltd. and Global Vice-President for Sales and Marketing, responsible for international expansion and market development.
- Dr. Ben Peacock: Head of Research, leading scientific application support and development initiatives.
Strategic Collaborations and Partnerships
NanoFCM has established several strategic partnerships to enhance its market presence and technological capabilities:
- RoosterBio, Inc.: In April 2023, NanoFCM partnered with RoosterBio, a leading supplier of human mesenchymal stem/stromal cells, designating them as an approved service provider for exosome analysis using the NanoAnalyzer platform.
- Exosomics SpA: In January 2020, Exosomics implemented NanoFCM's NanoAnalyzer to offer advanced extracellular vesicle-focused analytical services, becoming an approved service supplier of nano-flow cytometry measurements.
- DKSH: In February 2021, NanoFCM entered into a strategic agreement with DKSH to promote the NanoAnalyzer range in key Asian markets, including Singapore, Taiwan, and Thailand.
Operational Insights
NanoFCM's NanoAnalyzer platform offers a flexible, high-throughput solution for both academic and private research organizations working on nanoparticle entities. Operating similarly to a conventional flow cytometer, it allows for the screening of a wide array of biological markers, whether present on the surface or inside the particle. Fluorescence-based detection can be performed using a vast array of commercially available fluorophores and familiar staining protocols. By simultaneously measuring the scatter signal for each particle, it is possible to derive the size characteristics of each subpopulation, as well as their absolute concentration.
Strategic Opportunities and Future Directions
NanoFCM is poised to capitalize on the growing demand for precise nanoparticle analysis in various scientific and medical fields. The company's focus on expanding its global footprint through strategic partnerships and the establishment of regional offices positions it well to meet the needs of a diverse clientele. Continued innovation in nano-flow cytometry technology and applications is expected to drive further growth and adoption of NanoFCM's solutions.
Contact Information
For more information about NanoFCM and its products, please visit their official website.
